Illumina, Inc., ILMN is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Illumina, Inc., ILMN has a market cap of 20056.26. Since its IPO date on the 7/28/2000, Illumina, Inc., ILMN performance year to date is -28.87%. Today Illumina, Inc., ILMN has gained -1.01%, with a current price of 135.15.
Ownership of the company is 0.70% for insider ownership while institutional ownership is 94.80%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 11.30%, with return on investment at 16.60%.
In terms of debt levels and profit levels, Illumina, Inc., ILMN is seeing a long-term debt/equity of 0.46. While Total debt/equity is 0.47. With a profit margin of 18.70%, this is combined with a gross margin of 69.90%, and operating margin of 24.80%. Illumina, Inc. ability to meet debt levels, with a current ratio of 3.6, while the quick ratio is 3.1.
For the last year Illumina, Inc., ILMN has seen a EPS growth of 30.50%. A performance for the year of -25.76%. The 52-week high is -31.21%, and the 52-week low is 6.33%. The average volume for Illumina, Inc., ILMN is 294393.
With a target price of 144.47, can Illumina, Inc., ILMN reach this target? Looking at the value indicators of Illumina, Inc., ILMN. Illumina, Inc. has a P/E of 45.65 and a forward P/E of 36.6. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.15. Illumina, Inc. also has a P/S and a P/B of 8.46 and 8.94 respectively. For P/cash, Illumina, Inc. has a value of 13.05, while it is 47.53 for P/free cash flow.
At the current price of 135.15, Illumina, Inc. has a dividend yield of *TBA. We see a return on equity of 21.80%.
Looking more long-term Illumina, Inc., is projected to get an EPS growth for the next five years of 14.51%. In the short-term an EPS growth of 12.21% in the next year is forecasted. This is after a EPS growth of 30.50% for this year and for the last five years a 28.90% growth has been seen.